Diferencia entre revisiones de «Raltegravir»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 6: | Línea 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Treatment-naive: | *Recommended as part of a regimen including [[Tenofovir]] plus Emtricitabine or Lamivudine | ||
*Treatment-naive: 400 mg BID or 1200 mg daily | |||
*Treatment-experienced: 400 mg BID | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Oral suspension (10 mg/mL): 6 mg/kg/dose BID | |||
*Maximum dose: 100 mg/dose | |||
==Special Populations== | ==Special Populations== | ||
| Línea 19: | Línea 22: | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
No dosage adjustment necessary | No dosage adjustment necessary | ||
==Contraindications== | ==Contraindications== | ||
| Línea 33: | Línea 35: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 9 hours | ||
*Metabolism: | *Metabolism: Hepatic glucuronidation | ||
*Excretion: | *Excretion: Renal | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Reverse transcriptase inhibitor | |||
==Comments== | ==Comments== | ||
| Línea 47: | Línea 49: | ||
==References== | ==References== | ||
<ref>https://www.uptodate.com/contents/raltegravir-drug-information?search=Raltegravir&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1#F5374911</ref> | |||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revisión del 06:57 19 mar 2018
Administration
- Type: Antiretroviral, Integrase inhibitor
- Dosage Forms: 400 mg, 600 mg tablet
- Routes of Administration: PO
- Common Trade Names: Isentress
Adult Dosing
- Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine
- Treatment-naive: 400 mg BID or 1200 mg daily
- Treatment-experienced: 400 mg BID
Pediatric Dosing
Oral suspension (10 mg/mL): 6 mg/kg/dose BID
- Maximum dose: 100 mg/dose
Special Populations
- Pregnancy Rating: C
- Lactation risk: Unknown
Renal Dosing
- Mild to Moderate renal disease: No dosage adjustment necessary
- ESRD on HD: Dose after dialysis on dialysis days
Hepatic Dosing
No dosage adjustment necessary
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Stevens-Johnson Syndrome
- Anaphylaxis
- Myopathy/Rhabdomyolysis
Common
- Hepatic- increased transaminases
Pharmacology
- Half-life: 9 hours
- Metabolism: Hepatic glucuronidation
- Excretion: Renal
Mechanism of Action
- Reverse transcriptase inhibitor